Alfred Weber

This inventor holds 28 USPTO granted patents and 12 published patent applications, plus 6 CIPO patents and 15 EPO patents, primarily in Biotechnology Assays. Top assignees: Baxalta Gmbh, Baxter Healthcare Sa, Baxter International Inc.. Active years: 2001-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alfred Weber. Retrieved from https://idiyas.com/inventor/alfred-weber-s2fjcyh3

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 28 (Patent Applications = 12)

% Patents Active = 92.9

CIPO Patents = 6 (Patent Applications = 3)

EPO Patents = 15 (Patent Applications = 22)

Average Co-Inventor Count = 4.7

ph-index = 4

Forward Citations = 85(Granted Patents)

Company Filing History:

Baxter International Inc.

patents

4. 5 out of 1,226

Takeda Pharmaceutical Company Limited

patents

5. 1 out of 67

Baxter Aktiengesellschaft

where one patent can have more than one assignee

Years Active: 2001-2026

Loading Chart...

Areas of Expertise:

Heparin-Insensitive Assay

Anti-Factor IX Padua Antibodies

Human Plasma-Derived IgG

Serine Proteases Removal

Brain Disease-Related IgGs

Hyaluronidase Co-Formulation

Autoantibodies Measurement

PEG Protein Conjugates

Physiologically Acceptable Polymers

Differentiating Protein Types

Modification-Dependent Activity Assays

Factor VIII Complex

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12716084 - Heparin-insensitive assay for factor XIa (2026-08-25),

2. 12365723 - Human plasma-derived IGG preparation enriched in anti-parvo B19 natural IGGS (2025-07-22),

3. 11999798 - Anti-factor IX padua antibodies (2024-06-04),

4. 11891431 - Removal of serine proteases by treatment with finely divided silicon dioxide (2024-02-06),

5. 11098132 - Anti-factor IX Padua antibodies (2021-08-24),

6. 10875906 - Removal of serine proteases by treatment with finely divided silicon dioxide (2020-12-29),

7. 10738107 - Methods to produce a human plasma-derived IgG preparation enriched in brain disease-related natural iggs (2020-08-11),

8. 10208106 - Removal of serine proteases by treatment with finely divided silicon dioxide (2019-02-19),

9. 9896501 - Methods to produce a human plasma-derived IgG preparation enriched in brain disease-related natural IgGs (2018-02-20),

10. 9708391 - Removal of serine proteases by treatment with finely divided silicon dioxide (2017-07-18),

11. 9556261 - Methods to produce a human plasma-derived IgG preparation enriched in brain disease-related natural IgGs (2017-01-31),

12. 9547016 - Method and compositions for specifically detecting physiologically acceptable polymer molecules (2017-01-17),

13. 9512172 - Ethanol dependence of alpha1 antitrypsin C-terminal Lys truncation by basic carboxypeptidases (2016-12-06),

14. 9468675 - Removal of serine proteases by treatment with finely divided silicon dioxide (2016-10-18),

15. 9274122 - Methods for determining active ingredients in pro-drug PEG protein conjugates with releasable PEG reagents (in vitro de-pegylation) (2016-03-01),

Title: The Innovations of Alfred Weber in the Field of Biomedical Engineering

Introduction

Alfred Weber is a prolific inventor based in Vienna, Austria, known for his significant contributions to the field of biomedical engineering. With a remarkable portfolio of 26 patents, he has innovated in areas that greatly enhance medical diagnostics and treatment techniques. His expertise and inventive spirit have positioned him as a leader in his domain.

Latest Patents

Among his latest patents, one notable invention is the development of anti-Factor IX Padua antibodies. This invention provides binding constructs, such as antibodies and antigen-binding fragments, that can be applied in methods of detecting Factor IX Padua in various samples. Furthermore, his second significant patent, related to the removal of serine proteases through treatment with finely divided silicon dioxide, introduces novel methods for reducing serine protease content in plasma-derived protein compositions. These methods not only improve the composition of such proteins but also lend themselves to managing and treating diseases associated with serine protease levels.

Career Highlights

Throughout his career, Alfred Weber has made substantial contributions while working at renowned companies like Baxalta GmbH and Baxter International Inc. His inventive work has often aimed at translating complex scientific ideas into practical medical solutions that cater to real-world challenges faced by healthcare providers.

Collaborations

Alfred's journey in the innovation landscape has been enriched by collaborations with esteemed colleagues, including Hans-Peter Schwarz and Wolfgang Teschner. These partnerships have fostered a collaborative environment that has spurred creativity and led to the advancement of groundbreaking ideas in biomedical research.

Conclusion

Alfred Weber's innovative spirit and dedication to enhancing medical methodologies have resulted in numerous patents that continue to influence the industry. His work demonstrates the vital intersection of science and practical application, ensuring that advancements in healthcare are both effective and accessible. As he continues to explore new frontiers, his contributions are sure to leave a lasting impact on the field of biomedical engineering.

Profile summary based on public USPTO records.